OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone(510) 775-0515
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees12
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte's earnings last quarter?
OncoCyte Corp (NYSEAMERICAN:OCX) issued its earnings results on Wednesday, August, 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting the consensus estimate of ($0.10). View OncoCyte's Earnings History.
When is OncoCyte's next earnings date?
What price target have analysts set for OCX?
5 brokers have issued 1-year price objectives for OncoCyte's shares. Their forecasts range from $6.00 to $7.75. On average, they expect OncoCyte's stock price to reach $6.94 in the next year. This suggests a possible upside of 308.1% from the stock's current price. View Analyst Price Targets for OncoCyte.
What is the consensus analysts' recommendation for OncoCyte?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoCyte.
Has OncoCyte been receiving favorable news coverage?
Media coverage about OCX stock has trended very negative on Monday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OncoCyte earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for OncoCyte.
Are investors shorting OncoCyte?
OncoCyte saw a increase in short interest in October. As of October 15th, there was short interest totalling 1,430,000 shares, an increase of 6.7% from the September 15th total of 1,340,000 shares. Based on an average trading volume of 199,600 shares, the days-to-cover ratio is currently 7.2 days. Approximately 4.0% of the company's shares are short sold. View OncoCyte's Current Options Chain.
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include Neptune Wellness Solutions (NEPT), Silence Therapeutics (SLN), ProMetic Life Sciences (PLI), Rafael (RFL), Pfenex (PFNX), CEL-SCI (CVM), Enochian Biosciences (ENOB), Neuren Pharmaceuticals (NEU), 22nd Century Group (XXII), Horizon Discovery Group (HZD), Emblem (EMC), Monash IVF Group (MVF), Acasti Pharma (ACST), Exicure (XCUR) and Exicure (XCUR).
What other stocks do shareholders of OncoCyte own?
Who are OncoCyte's key executives?
OncoCyte's management team includes the folowing people:
- Mr. William Annett, Pres, CEO & Director (Age 65)
- Mr. Mitchell S. Levine, Chief Financial Officer
- Dr. Lyndal K. Hesterberg, Chief Scientific Officer
- Mr. Albert P. Parker II, Chief Operating Officer
- Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)
Who are OncoCyte's major shareholders?
OncoCyte's stock is owned by a number of of retail and institutional investors. Top institutional investors include Emerald Mutual Fund Advisers Trust (4.68%). Company insiders that own OncoCyte stock include Andrew Arno, Biotime Inc, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Institutional Ownership Trends for OncoCyte.
Which institutional investors are buying OncoCyte stock?
OCX stock was purchased by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust. Company insiders that have bought OncoCyte stock in the last two years include Andrew Arno, Broadwood Partners, LP, Mitchell S Levine and Thomas Alex Vetter. View Insider Buying and Selling for OncoCyte.
How do I buy shares of OncoCyte?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OncoCyte's stock price today?
One share of OCX stock can currently be purchased for approximately $1.70.
How big of a company is OncoCyte?
What is OncoCyte's official website?
How can I contact OncoCyte?
OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.
MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
